{ "labelLang" : "hun", "responseDate" : "2024-03-29 16:37", "content" : { "otype" : "JournalArticle", "mtid" : 25984138, "status" : "ADMIN_APPROVED", "published" : true, "comment" : "National Cancer Institute, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, 1050 Boyles Street, Frederick, 21702-1201, United States \n Department of Internal Medicine 1, University of Erlangen-Nuremberg, Erlangen, Germany \n Cited By :24 \n Export Date: 5 August 2020 \n CODEN: IBDNB \n Correspondence Address: McLean, M.H.; National Cancer Institute, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, 1050 Boyles Street, Frederick, 21702-1201, United States; email: mairi.mclean@nih.gov\nNational Cancer Institute, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, 1050 Boyles Street, Frederick, 21702-1201, United States \n Department of Internal Medicine 1, University of Erlangen-Nuremberg, Erlangen, Germany \n Cited By :24 \n Export Date: 1 October 2020 \n CODEN: IBDNB \n Correspondence Address: McLean, M.H.; National Cancer Institute, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, 1050 Boyles Street, Frederick, 21702-1201, United States; email: mairi.mclean@nih.gov \n Chemicals/CAS: interleukin 18, 189304-55-0; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; Immunologic Factors; Interleukins; Tumor Necrosis Factor-alpha\nFunding Agency and Grant Number: National Institutes of Health, National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); Crohn's and Colitis Foundation of America; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [ZIABC011150] Funding Source: NIH RePORTER\n Funding text: Supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. Fellowship funded by Crohn's and Colitis Foundation of America (M.H.M.).\nNational Cancer Institute, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, 1050 Boyles Street, Frederick, 21702-1201, United States \n Department of Internal Medicine 1, University of Erlangen-Nuremberg, Erlangen, Germany \n Cited By :28 \n Export Date: 2 July 2021 \n CODEN: IBDNB \n Correspondence Address: McLean, M.H.; National Cancer Institute, 1050 Boyles Street, Frederick, 21702-1201, United States; email: mairi.mclean@nih.gov", "unhandledTickets" : 0, "oldTimestamp" : "2017-05-28T18:06:55.000+0000", "deleted" : false, "oldId" : 15984138, "lastRefresh" : "2022-02-12T08:32:39.282+0000", "lastModified" : "2019-04-20T11:16:51.228+0000", "created" : "2016-08-15T12:40:17.000+0000", "creator" : { "otype" : "Author", "mtid" : 10011481, "link" : "/api/author/10011481", "label" : "Dank Magdolna (onkológia)", "familyName" : "Dank", "givenName" : "Magdolna", "published" : true, "oldId" : 10011481, "snippet" : true }, "lastDuplumOK" : "2021-12-19T18:43:38.685+0000", "lastDuplumSearch" : "2021-12-19T18:43:38.685+0000", "adminApproved" : "2016-08-15T12:55:44.000+0000", "adminApprover" : { "otype" : "Admin", "mtid" : 10015544, "link" : "/api/admin/10015544", "label" : "Csajbók Edit (SE_KK_Admin5_CSE, admin)", "familyName" : "Csajbók", "givenName" : "Edit", "published" : true, "oldId" : 10015544, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Összefoglaló cikk (Folyóiratcikk)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "McLean, MH", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 58495699, "link" : "/api/authorship/58495699", "label" : "McLean, MH", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "familyName" : "McLean", "givenName" : "MH", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 119808664, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 58495700, "link" : "/api/authorship/58495700", "label" : "Neurath, MF", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "familyName" : "Neurath", "givenName" : "MF", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 119808663, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 58495701, "link" : "/api/authorship/58495701", "label" : "Durum, SK", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : true, "familyName" : "Durum", "givenName" : "SK", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 119808662, "snippet" : true } ], "title" : "Targeting interleukins for the treatment of inflammatory bowel disease - What lies beyond anti-TNF therapy?", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 11354584, "link" : "/api/publicationidentifier/11354584", "label" : "DOI: 10.1097/01.MIB.0000437616.37000.41", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1097/01.MIB.0000437616.37000.41", "realUrl" : "https://doi.org/10.1097%2F01.MIB.0000437616.37000.41", "published" : false, "oldId" : 13043434, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 7032921, "link" : "/api/publicationidentifier/7032921", "label" : "WoS: 000335790000025", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=CustomerName&SrcApp=CustomerName&DestLinkType=FullRecord&KeyUT=@@@&DestApp=WOS", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000335790000025", "realUrl" : "http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=CustomerName&SrcApp=CustomerName&DestLinkType=FullRecord&KeyUT=000335790000025&DestApp=WOS", "published" : false, "oldId" : 6903868, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 11354583, "link" : "/api/publicationidentifier/11354583", "label" : "Scopus: 84893764923", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "84893764923", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-84893764923", "published" : false, "oldId" : 13043433, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 15557484, "link" : "/api/publicationidentifier/15557484", "label" : "PubMed: 24356385", "source" : { "otype" : "PlainSource", "mtid" : 17, "link" : "/api/publicationsource/17", "label" : "PubMed", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "PubMed", "nameEng" : "PubMed", "linkPattern" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract", "publiclyVisible" : true, "published" : true, "oldId" : 17, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "24356385", "realUrl" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24356385&dopt=Abstract", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 17842, "link" : "/api/journal/17842", "label" : "INFLAMMATORY BOWEL DISEASES 1078-0998 1536-4844", "pIssn" : "1078-0998", "eIssn" : "1536-4844", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 17842, "snippet" : true }, "volume" : "20", "issue" : "2", "firstPage" : "389", "lastPage" : "397", "firstPageOrInternalIdForSort" : "389", "pageLength" : 9, "publishedYear" : 2014, "digital" : null, "printed" : null, "sourceYear" : 2016, "packet" : "325399", "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2022-02-12", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 2, "citedCount" : 2, "ratings" : [ { "otype" : "SjrRating", "mtid" : 11079843, "link" : "/api/sjrrating/11079843", "label" : "sjr:D1 (2014) Scopus - Gastroenterology INFLAMMATORY BOWEL DISEASES 1078-0998 1536-4844", "listPos" : 8, "rankValue" : 0.1, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 2715, "link" : "/api/classificationexternal/2715", "label" : "Scopus - Gastroenterology", "published" : true, "oldId" : 2715, "snippet" : true }, "ranking" : "D1", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "D1", "referenceList" : "Danese, S., Fiocchi, C., Ulcerative colitis (2011) N Engl J Med., 365, pp. 1713-1725; \n\nBurisch, J., Jess, T., Martinato, M., The burden of inflammatory bowel disease in Europe (2013) J Crohns Colitis., 7, pp. 322-337; \n\nBurisch, J., Munkholm, P., Inflammatory bowel disease epidemiology (2013) Curr Opin Gastroenterol., 29, pp. 357-362; \n\nMolodecky, N.A., Soon, I.S., Rabi, D.M., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review (2012) Gastroenterology., 142, pp. 46-54; \n\nKaser, A., Zeissig, S., Blumberg, R.S., Inflammatory bowel disease (2010) Annu Rev Immunol., 28, pp. 573-621; \n\nScharl, M., Rogler, G., Inflammatory bowel disease pathogenesis: What is new? (2012) Curr Opin Gastroenterol., 28, pp. 301-309; \n\nAhluwalia, J.P., Immunotherapy in inflammatory bowel disease (2012) Med Clin North Am., 96, pp. 525-544; \n\nFord, A.C., Sandborn, W.J., Khan, K.J., Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis (2011) Am J Gastroenterol., 106, pp. 644-659; \n\nRandall, C., Vizuete, J., Wendorf, G., Current and emerging strategies in the management of Crohn's disease (2012) Best Pract Res Clin Gastroenterol., 26, pp. 601-610; \n\nLöwenberg, M., D'haens, G., Novel targets for inflammatory bowel disease therapeutics (2013) Curr Gastroenterol Rep., 15, p. 311; \n\nDanese, S., Colombel, J.F., Peyrin-Biroulet, L., Review article: The role of anti-TNF in the management of ulcerative colitis-past, present and future (2013) Aliment Pharmacol Ther., 37, pp. 855-866; \n\nRietdijk, S.T., D'haens, G.R., Recent developments in the treatment of inflammatory bowel disease (2013) J Dig Dis., 14, pp. 282-287; \n\nSandborn, W.J., Feagan, B.G., Marano, C.W., Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis (2014) Gastroenterology., 146, pp. 96-109; \n\nDinarello, C.A., Immunological and inflammatory functions of the interleukin-1 family (2009) Annu Rev Immunol., 27, pp. 519-550; \n\nBen-Sasson, S.Z., Hu-Li, J., Quiel, J., IL-1 acts directly on CD4+ T cells to enhance their antigen-driven expansion and differentiation (2009) Proc Natl Acad Sci U S A., 106, pp. 7119-7124; \n\nCoccia, M., Harrison, O.J., Schiering, C., IL-1b mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells (2012) J Exp Med., 209, pp. 1595-1609; \n\nCiraci, C., Janczy, J.R., Sutterwala, F.S., Control of innate and adaptive immunity by the inflammasome (2012) Microbes Infect., 14, pp. 1263-1270; \n\nMahida, Y.R., Wu, K., Jewell, D.P., Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease (1989) Gut., 30, pp. 835-838; \n\nRugtveit, J., Nilsen, E.M., Bakka, A., Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease (1997) Gastroenterology., 112, pp. 1493-1505; \n\nLudwiczek, O., Vannier, E., Borggraefe, I., Imbalance between interleukin-1 agonists and antagonists: Relationship to severity of inflammatory bowel disease (2004) Clin Exp Immunol., 138, pp. 323-329; \n\nMcAlindon, M.E., Hawkey, C.J., Mahida, Y.R., Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease (1998) Gut., 42, pp. 214-219; \n\nCominelli, F., Nast, C.C., Duchini, A., Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis (1992) Gastroenterology., 103, pp. 65-71; \n\nThomas, T.K., Will, P.C., Srivastava, A., Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model (1991) Agents Actions., 34, pp. 187-190; \n\nSiegmund, B., Lehr, H.A., Fantuzzi, G., IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation (2001) Proc Natl Acad Sci U S A., 98, pp. 13249-13254; \n\nMaeda, S., Hsu, L.C., Liu, H., Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing (2005) Science., 307, pp. 734-738; \n\nLacruz-Guzmán, D., Torres-Moreno, D., Pedrero, F., Influence of polymorphisms and TNF and IL1b serum concentration on the infliximab response in Crohn's disease and ulcerative colitis (2013) Eur J Clin Pharmacol., 69, pp. 431-438; \n\nYamamoto-Furusho, J.K., Santiago-Hernández, J.J., Perez-Hernandez, N., Interleukin 1 b (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis (2011) J Clin Gastroenterol., 45, pp. 531-535; \n\nDinarello, C.A., Simon, A., Van Der Meer, J.W., Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases (2012) Nature Rev Drug Discov., 11, pp. 633-652; \n\nPizarro, T.T., Michie, M.H., Bentz, M., IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells (1999) J Immunol., 162, pp. 6829-6835; \n\nKanai, T., Watanabe, M., Okazawa, A., Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease (2000) Gastroenterology., 119, pp. 1514-1553; \n\nTen Hove, T., Corbaz, A., Amitai, H., Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice (2001) Gastroenterology., 121, pp. 1372-1379; \n\nSivakumar, P.V., Westrich, G.M., Kanaly, S., Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: Blocking interleukin 18 attenuates intestinal damage (2002) Gut., 50, pp. 812-820; \n\nWirtz, S., Becker, C., Blumberg, R., Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA (2002) J Immunol., 168, pp. 411-420; \n\nTakagi, H., Kanai, T., Okazawa, A., Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice (2003) Scand J Gastroenterol., 38, pp. 837-844; \n\nHirota, S.A., Ng, J., Lueng, A., NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis (2011) Inflamm Bowel Dis., 17, pp. 1359-1372; \n\nZaki, M.H., Boyd, K.L., Vogel, P., The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis (2010) Immunity., 32, pp. 379-391; \n\nBeltran, C.J., Nunez, L.E., Diaz-Jimenez, D., Characterization of the novel ST2/ IL-33 system in patients with inflammatory bowel disease (2010) Inflamm Bowel Dis., 16, pp. 1097-1107; \n\nSeidelin, J.B., Bjerrum, J.T., Coskun, M., IL-33 is upregulated in colonocytes of ulcerative colitis (2010) Immunol Lett., 128, pp. 80-85; \n\nPastorelli, L., Garg, R.R., Hoang, S.B., Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/ Th2 driven enteritis (2010) Proc Natl Acad Sci U S A., 107, pp. 8017-8022; \n\nKobori, A., Yagi, Y., Imaeda, H., Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis (2010) J Gastroenterol., 45, pp. 999-1007; \n\nSedhom, M.A.K., Pichery, M., Murdoch, J.R., Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice (2013) Gut., 62, pp. 1714-1723; \n\nNeill, D.R., Wong, S.H., Bellosi, A., Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity (2010) Nature., 464, pp. 1367-1370; \n\nSeidelin, J.B., Rogler, G., Nielsen, O.H., A role for interleukin-33 in T(H)2- polarized intestinal inflammation? (2011) Mucosal Immunol., 4, pp. 496-502; \n\nHaraldsen, G., Balogh, J., Pollheimer, J., Interleukin-33-cytokine of dual function or novel alarmin? (2009) Trends Immunol., 30, pp. 227-233; \n\nO'connor, P.M., Lapointe, T.K., Beck, P.L., Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease (2010) Inflamm Bowel Dis., 16, pp. 1411-1420; \n\nWaldner, M.J., Foersch, S., Neurath, M.F., Interleukin-6-A key regulator of colorectal cancer development (2012) Int J Biol Sci., 8, pp. 1248-1253; \n\nMitsuyama, K., Sata, M., Rose-John, S., Interleukin-6 trans-signaling in inflammatory bowel disease (2006) Cytokine Growth Factor Rev., 17, pp. 451-461; \n\nIsaacs, K.L., Sartor, R.B., Haskill, S., Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification (1992) Gastroenterology., 103, pp. 1587-1595; \n\nReinecker, H.C., Steffen, M., Witthöft, T., Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease (1993) Clin Exp Immunol., 94, pp. 174-181; \n\nAtreya, R., Mudter, J., Finotto, S., Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo (2000) Nat Med., 6, pp. 583-588; \n\nGross, V., Andus, T., Caesar, I., Evidence for continuous stimulation of interleukin-6 production in Crohn's disease (1992) Gastroenterology., 102, pp. 514-519; \n\nHolub, M.C., Mako, E., Devay, T., Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease (1998) Scand J Gastroenterol., 228, pp. 47-50; \n\nLouis, E., Belaiche, J., Van Kemseke, C., A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease (1997) Eur J Gastroenterol Hepatol., 9, pp. 939-944; \n\nReinisch, W., Gasche, C., Tillinger, W., Clinical relevance of serum interleukin-6 in Crohn's disease: Single point measurements, therapy monitoring, and prediction of clinical relapse (1999) Am J Gastroenterol., 94, pp. 2156-2164; \n\nVan Kemseke, C., Belaiche, J., Louis, E., Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission (2000) Int J Colorectal Dis., 15, pp. 206-210; \n\nMizutani, T., Akasaka, R., Tomita, K., Serial changes of cytokines in Crohn's disease treated with infliximab (2011) Hepatogastroenterology., 58, pp. 110-111; \n\nCarey, R., Jurickova, I., Ballard, E., Activation of an IL-6: STAT3- dependent transcriptome in pediatric-onset inflammatory bowel disease (2008) Inflamm Bowel Dis., 14, pp. 446-457; \n\nYamamoto, M., Yoshizaki, K., Kishimoto, T., IL-6 is required for the development of Th1 cell-mediated murine colitis (2000) J Immunol., 164, pp. 4878-4882; \n\nSuzuki, T., Yoshinaga, N., Tanabe, S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium (2011) J Biol Chem., 286, pp. 31263-31271; \n\nIto, H., Takazoe, M., Fukuda, Y., A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease (2004) Gastroenterology., 126, pp. 989-996; \n\nPhase 1 Study of Safety and Biological Effects of C326, An Inhibitor of IL-6, in Crohn's Disease, , http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00353756, ClinicalTrials.gov, NCT00353756 Available at Accessed November 4, 2013; \n\nSilverman, J., Liu, Q., Bakker, A., Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains (2005) Nat Biotechnol., 23, pp. 1556-1561; \n\nNeurath, M.F., Finotto, S., IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer (2011) Cytokine Growth Factor Rev., 22, pp. 83-89; \n\nGrivennikov, S., Karin, E., Terzic, J., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer (2009) Cancer Cell., 15, pp. 103-113; \n\nBecker, C., Fantini, M.C., Schramm, C., TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 transsignaling (2004) Immunity., 21, pp. 491-501; \n\nMatsumoto, S., Hara, T., Mitsuyama, K., Essential roles of IL-6 transsignaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model (2010) J Immunol., 184, pp. 1543-1551; \n\nWojno, E.D., Hunter, C.A., New directions in the basic and translational biology of interleukin-27 (2012) Trends Immunol., 33, pp. 91-97; \n\nPflanz, S., Timans, J.C., Cheung, J., IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells (2002) Immunity., 16, pp. 779-790; \n\nOmata, F., Birkenbach, M., Matsuzaki, S., The expression of IL-12 p40 and its homologue, Epstein-Barr virus-induced gene 3, in inflammatory bowel disease (2001) Inflamm Bowel Dis., 7, pp. 215-220; \n\nSchmidt, C., Giese, T., Ludwig, B., Expression of interleukin- 12-related cytokine transcripts in inflammatory bowel disease: Elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis (2005) Inflamm Bowel Dis., 11, pp. 16-23; \n\nApetoh, L., Quintana, F.J., Pot, C., The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27 (2010) Nat Immunol., 11, pp. 854-861; \n\nPot, C., Apetoh, L., Awasthi, A., Molecular pathways in the induction of interleukin-27-driven regulatory type 1 cells (2010) J Interferon Cytokine Res., 30, pp. 381-388; \n\nPot, C., Apetoh, L., Awasti, A., Induction of regulatory Tr1 cells and inhibition of TH17 cells by IL-27 (2011) Semin Immunol., 23, pp. 438-445; \n\nHonda, K., Nakamura, K., Matsui, N., T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis (2005) Inflamm Bowel Dis., 11, pp. 1044-1052; \n\nTroy, A.E., Zaph, C., Du, Y., IL-27 regulates homeostasis of the intestinal CD4+ effector T cell pool and limits intestinal inflammation in a murine model of colitis (2009) J Immunol., 183, pp. 2037-2044; \n\nSasaoka, T., Ito, M., Yamashita, J., Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells (2011) Am J Physiol-Gastroenterol., 300, pp. G568-G576; \n\nCox, J.H., Kljavin, M.M., Ramamoorthi, N., IL-27 promotes T celldependent colitis through multiple mechanisms (2011) J Exp Med., 208, pp. 115-123; \n\nWirtz, S., Billmeier, U., McHedlidze, T., Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis (2011) Gastroenterology., 141, pp. 1875-1886; \n\nHanson, M.L., Hixon, J.A., Li, W.Q., Oral delivery of IL27 recombinant bacteria attenuates immune colitis in mice (2014) Gastroenterology, 146, pp. 210-221; \n\nMcLean, M.H., Hanson, M.L., Steidler, L., Intra-luminal interleukin (IL)-27 ameliorates acute murine tnbs colitis - A potential future therapeutic for inflammatory bowel disease (2013) Gastroenterology., 144 (SUPPL. 1), pp. S-33; \n\nGuzzo, C., Ayer, A., Basta, S., IL-27 enhances LPS-induced proinflammatory cytokine production via upregulation of TLR4 expression and signaling in human monocytes (2012) J Immunol., 188, pp. 864-873; \n\nLi, J.P., Wu, H., Xing, W., Interleukin-27 as a negative regulator of human neutrophil function (2010) Scand J Immunol., 72, pp. 284-292; \n\nDiegelmann, J., Olszak, T., Göke, B.J., A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins (2012) J Biol Chem., 287, pp. 286-298; \n\nImielinski, M., Baldassano, R.N., Griffiths, A., Common variants at five new loci associated with early-onset inflammatory bowel disease (2009) Nat Genet., 41, pp. 1335-1340; \n\nCollison, L.W., Workman, C.J., Kuo, T.T., The inhibitory cytokine IL-35 contributes to regulatory T-cell function (2007) Nature., 450, pp. 566-569; \n\nNiedbala, W., Wei, X.Q., Cai, B., IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells (2007) Eur J Immunol., 37, pp. 3021-3029; \n\n(2007) Eur J Immunol, 37, p. 3293; \n\nCollison, L.W., Chaturvedi, V., Henderson, A.L., IL-35-mediated induction of a potent regulatory T cell population (2010) Nat Immunol., 11, pp. 1093-1101; \n\nChaturvedi, V., Collison, L.W., Guy, C.S., Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance (2011) J Immunol., 186, pp. 6661-6666; \n\nCollison, L.W., Vignali, D.A., Interleukin-35: Odd one out or part of the family? (2008) Immunol Rev., 226, pp. 248-262; \n\nYe, S., Wu, J., Zhou, L., Interleukin-35: The future of hyperimmunerelated diseases? (2013) J Interferon Cytokine Res., 33, pp. 285-291; \n\nCamoglio, L., Juffermans, N.P., Peppelenbosch, M., Contrasting roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis (2002) Eur J Immunol., 32, pp. 261-269; \n\nYen, D., Cheung, J., Scheerens, H., IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6 (2006) J Clin Invest., 116, pp. 1310-1316; \n\nSonnenberg, G.F., Fouser, L.A., Artis, D., Border patrol: Regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22 (2011) Nat Immmunol., 12, pp. 383-390; \n\nAndoh, A., Zhang, Z., Inatomi, O., Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts (2005) Gastroenterology., 129, pp. 969-984; \n\nBrand, S., Beigel, F., Olszak, T., IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration (2006) Am J Physiol Gastrointest Liver Physiol., 290, pp. G827-G838; \n\nYamamoto-Furusho, J.K., Miranda-Perez, E., Fonseca-Camarillo, G., Colonic epithelial upregulation of interleukin 22 (IL-22) in patients with ulcerative colitis (2010) Inflamm Bowel Dis., 16, p. 1823; \n\nSekikawa, A., Fukui, H., Suzuki, K., Involvement of the IL-22/REG Ia axis in ulcerative colitis (2010) Lab Invest., 90, pp. 496-505; \n\nYu, L.Z., Wang, H.Y., Yang, S.P., Expression of interleukin-22/STAT3 signalling pathway in ulcerative colitis and related carcinogenesis (2013) World J Gastroenterol., 19, pp. 2638-2649; \n\nJiang, R., Wang, H., Deng, L., IL-22 is related to development of human colon cancer by activation of STAT3 (2013) BMC Cancer., 13, p. 59; \n\nSchmechel, S., Konrad, A., Diegelmann, J., Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status (2008) Inflamm Bowel Dis., 14, pp. 204-212; \n\nZenewicz, L.A., Yancopoulos, G.D., Valenzuela, D.M., Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease (2008) Immunity., 29, pp. 947-957; \n\nMonteleone, I., Rizzo, A., Sarra, M., Aryl hydrocarbon receptor induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract (2011) Gastroenterology., 141, pp. 237-248; \n\nCox, J.H., Kljavin, N.M., Ota, N., Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice (2012) Mucosal Immunol., 5, pp. 99-109; \n\nZheng, Y., Valdez, P.A., Danilenko, D.M., Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens (2008) Nat Med., 14, pp. 282-289; \n\nPickert, G., Neufert, C., Leppkes, M., STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing (2009) J Exp Med., 206, pp. 1465-1472; \n\nSugimoto, K., Ogawa, A., Mizoguchi, E., IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis (2008) J Clin Invest., 118, pp. 534-544; \n\nMizoguchi, E., Xavier, R.J., Reinecker, H.C., Colonic epithelial functional phenotype varies with type and phase of experimental colitis (2003) Gastroenterology., 125, pp. 148-161; \n\nMizoguchi, A., Healing of intestinal inflammation by IL-22 (2012) Inflamm Bowel Dis., 18, pp. 1777-1784; \n\nKotenko, S.V., Izotora, L.S., Mirochnitchenko, O.V., Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity (2001) J Immunol., 166, pp. 7096-7103; \n\nXu, W., Presnell, S.R., Parrish-Novak, J., A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist (2001) Proc Natl Acad Sci U S A., 98, pp. 9511-9516; \n\nHuber, S., Gagliani, N., Zenewicz, L.A., IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine (2012) Nature., 491, pp. 259-263; \n\nPapp, K.A., Menter, A., Strober, B., Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A phase 2b randomized placebo-controlled dose-ranging study (2012) Br J Dermatol., 167, pp. 668-677; \n\nVan Vollenhoven, R.F., Fleischmann, R., Cohen, S., Tofacitinib or adalimumab versus placebo in rheumatoid arthritis (2012) N Engl J Med., 367, pp. 508-519; \n\nFleischmann, R., Kremer, J., Cush, J., Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis (2012) N Engl J Med., 367, pp. 495-507; \n\nSandborn, W.J., Ghosh, S., Panes, J., Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis (2012) N Engl J Med., 367, pp. 616-624; \n\nSandborn, W.J., Ghosh, S., Panes, J., Phase 2 randomized study of CP- 690,550, an oral Janus kinase inhibitor, in active Crohn's disease (2011) Gastroenterology., 140 (SUPPL.), pp. S124-S124; \n\nPaul, S., Roblin, X., Tofacitinib in active ulcerative colitis (2012) N Engl J Med., 367, pp. 1959-1960; \n\nCottone, M., Orlando, A., Papi, C., Tofacitinib in active ulcerative colitis (2012) N Engl J Med., 367, p. 1960; \n\nPeyrin-Biroulet, L., Danese, S., Tofacitinib: Janus bifrons in ulcerative colitis treatment (2013) Gastroenterology., 144, pp. 1136-1138; \n\nVuitton, L., Koch, S., Peyrin-Biroulet, L., Janus kinase inhibition with tofacitinib: Changing the face of inflammatory bowel disease treatment (2013) Curr Drug Targets., 14, pp. 1385-1391; \n\nLangrish, C.L., McKenzie, B.S., Wilson, N.J., IL-12 and IL-23: Master regulators of innate and adaptive immunity (2004) Immunol Rev., 202, pp. 96-105; \n\nUhlig, H.H., McKenzie, B.S., Hue, S., Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology (2006) Immunity., 25, pp. 309-318; \n\nNeurath, M.F., IL-23: A master regulator in Crohn disease (2007) Nat Med., 13, pp. 26-28; \n\nZhang, Z., Hinrichs, D.J., Lu, H., After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease (2007) Int Immunopharmacol., 7, pp. 409-416; \n\nNeurath, M.F., Fuss, I., Kelsall, B.L., Antibodies to interleukin 12 abrogate established experimental colitis in mice (1995) J ExpMed., 182, pp. 1281-1290; \n\nDuerr, R.H., Taylor, K.D., Brant, S.R., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene (2006) Science., 314, pp. 1461-1463; \n\nKim, S.W., Kim, E.S., Moon, C.M., Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease (2011) Gut., 60, pp. 1527-1536; \n\nAnderson, C.A., Boucher, G., Lees, C.W., Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 (2011) Nat Genet., 43, pp. 246-252; \n\nSandborn, W.J., Feagan, B.G., Fedorak, R.N., A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease (2008) Gastroenterology., 135, pp. 1130-1141; \n\nSandborn, W.J., Gasink, C., Gao, L.L., Ustekinumab induction and maintenance therapy in refractory Crohn's disease (2012) N Engl J Med., 367, pp. 1519-1528; \n\nSteidler, L., Hans, W., Schotte, L., Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 (2000) Science., 289, pp. 1352-1355", "hasCitationDuplums" : false, "userChangeableUntil" : "2016-08-15T12:55:44.000+0000", "publishDate" : "2016-08-15T12:55:40.000+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 6, "ownerInstituteCount" : 21, "directInstituteCount" : 0, "authorCount" : 3, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/25984138", "label" : "McLean MH et al. Targeting interleukins for the treatment of inflammatory bowel disease - What lies beyond anti-TNF therapy?. (2014) INFLAMMATORY BOWEL DISEASES 1078-0998 1536-4844 20 2 389-397", "template" : "